Table 4A. Acute (2-day) toxicity of 89Zr-DFO-nimotuzumab.
| Parameters | Male ± Std Dev.* | Female ± Std Dev.** | ||
|---|---|---|---|---|
| Clinical chemistry | Control treated | 89Zr-DFO-nimotuzumab | Control treated | 89Zr-DFO-nimotuzumab |
| Albumin:Globulin (g/L) | 1.61 ± 0.13 | 1.51 ± 0.05 | 2.08 ± 0.13 | 2.01 ± 0.22 |
| Albumin (g/L) | 29.21 ± 1.09 | 29.0 ± 0.70 | 32.8 ± 1.48 | 32.0 ± 1.41 |
| Globulin (g/L) | 18.2 ± 0.84 | 19.2 ± 0.44 | 15.8 ± 1.09 | 16.0 ± 1.22 |
| Alkaline Phosphatase (U/L) | 146.41 ± 11.39 | 139.60 ± 9.91 | 147.20 ± 6.38 | 140.80 ± 2.59 |
| ALT (U/L) | 24.21 ± 2.58 | 25.81 ± 1.3 | 25.80 ± 5.76 | 26.60 ± 4.51 |
| AST (U/L) | 69.81 ± 9.85 | 83.21 ± 17.98 | 116.4 ± 82.50 | 73.0 ± 15.02 |
| Bicarbonate (mmol/L) | 17.01 ± 0.7 | 17.41 ± 1.14 | 15.4 ± 2.97 | 18.0 ± 0.70 |
| Ca2+ (mmol/L) | 2.48 ± 0.07 | 2.39 ± 0.14 | 2.28 ± 0.04 | 2.37 ± 0.13 |
| Cl−1 (mmol/L) | 109.20 ± 1.483 | 108.2 ± 0.83 | 106.0 ± 4.12 | 108.0 ± 2.12 |
| Creatinine | 14.6 ± 1.67 | 12.8 ± 2.59 | 18.0 ± 5.43 | 14.41 ± 3.05 |
| Glucose (mmol/L) | 13.68 ± 1.70 | 12.68 ± 1.29 | 14.02 ± 1.72 | 12.50 ± 1.11 |
| K+ (mmol/L) | 5.12 ± 0.55 | 6.48 ± 0.69 | 5.12 ± 0.85 | 5.1 ± 0.73 |
| Na+ (mmol/L) | 147.8 ± 1.79 | 145.0 ± 1.58 | 142.20 ± 4.44 | 144.2 ± 1.92 |
| Na+/Ka+ | 29.41 ± 2.9 | 22.4 ± 2.4 | 28.40 ± 4.80 | 28.8 ± 4.87 |
| Total bilirubin (μmol/L) | 1.28 ± 0.39 | 1.42 ± 0.39 | 0.36 ± 0.33 | 0.96 ± 0.15 |
| Total protein (g/L) | 47.4 ± 0.54 | 48.2 ± 0.83 | 48.6 ± 2.19 | 48.0 ± 1.4 |
| Urea (mmol/L) | 6.86 ± 0.6 | 7.30 ± 0.89 | 6.86 ± 0.6 | 7.30 ± 0.88 |
| Cell Blood Counts | ||||
| HCT (L/L) | 0.47 ± 0.05 | 0.47 ± 0.02 | 0.48 ± 0.02 | 0.48 ± 0.01 |
| HGB (g/L) | 144.0 ± 12.73 | 144.2 ± 5.77 | 148.20 ± 3.96 | 150.40 ± 3.05 |
| MCH (pg) | 15.05 ± 0.19 | 14.9 ± 0.22 | 15.21 ± 0.10 | 15.18 ± 0.16 |
| MCHC (g/L) | 307.3 ± 4.99 | 307.6 ± 3.8 | 309.80 ± 3.63 | 315.0 ± 5.29 |
| MCV (fL) | 48.93 ± 0.3 | 48.42 ± 0.44 | 48.96 ± 0.48 | 48.14 ± 0.42 |
| RBC (x1012/L) | 9.55 ± 0.92 | 9.68 ± 0.37 | 9.76 ± 0.3 | 9.92 ± 0.23 |
| RDW (%) | 14.35 ± 0.47 | 14.26 ± 0.47 | 14.98 ± 0.41 | 14.90 ± 0.32 |
| WBC (x109/L) | 2.45 ± 1.59 | 2.9 ± 1.50 | 3.06 ± 0.90 | 2.08 ± 0.64 |
* (male) and ** (female): There were no significant differences in all parameters between control treated and 89Zr-DFO-nimotuzumab treated mice following injection of excess of 89Zr-DFO-nimotuzumab.